Odyssey Therapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Odyssey Therapeutics (clinical-stage biotech, $483.9M assets) reported Q3 2026 cash position of $387M (80% of total assets), sufficient to fund operations into H2 2028. OD-001 Phase 2a induction results presented in October showed clinical efficacy supported by biomarker and transcriptomic findings in ulcerative colitis (56 efficacy-evaluable patients). IND-enabling studies completed for OD-002, a first-in-class oral SLC15A4 inhibitor; Phase 1/2a trial initiation expected H1 2027. Q3 net loss was $53.1M versus $35.5M in Q3 2025; R&D expenses increased to $42.1M from $26.3M year-over-year. Leadership appointments: Anthony Opipari, M.D., Ph.D. as chief medical officer and Laura Hare as chief people officer.
Why this rating
Strong cash runway (80% of assets) and clinical proof-of-concept data reduce near-term dilution risk. OD-002 IND-filing imminent. Elevated burn rate ($53M/quarter) is material but manageable. Leadership continuity supports execution.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.